BiVictriX are delighted to be announced winner of the Runner-Up Award for Best Poster at World ADC San Diego 2019, the leading global ADC conference. This marks the Company's inaugural attendance at the meeting and the first time the Company has disclosed preclinical data on the lead program, BVX001, a bispecific antibody drug-conjugate (ADC) targeting a highly aggressive form of leukaemia called Acute Myeloid Leukaemia (AML).
The lead program represents the world's first genuine bispecific antibody drug-conjugate in development demonstrating improved efficacy together with substantially decreased toxicity. The program exploits the Company's innovative Bi-Cygni technology, enabling the delivery of a new class of biotherapeutics with improved potency and substantially wider therapeutic indices.
The presentations were judged by a panel of world leading ADC experts who recognised BiVictriX's data as one of the most important data presentations in the field. Recognition at such an early stage in the Company's development provides further validation of the significant need that exists within the industry to improve the cancer specificity of biotherapeutics, enabling development of next-generation approaches.
